Jose Cortes, MD
Internal Medicine · New York, NYNPI 1710077409
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $131,488 of the $183,575 with a category attached, or 71.6%. Gilead accounts for 67.6% of it on its own, with 48 other manufacturers making up the rest. 2025 is the largest year on record at $85,938, 2.1 times the $40,243 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,147 payments — averaging $160.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$124K
- Viiv Healthcare Company$48K
- Merck$2K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Johnson & Johnson$778
- plus $6K from 43 others
What the payments were for
- Consulting fees$3,1402%
- Speaking & faculty fees$131,48872%
- Travel & lodging$22,27012%
- Food & beverage$26,38414%
- Education$2940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$183,575 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 262 | $1,055,466 |
| JanuviaSitagliptin Phosphate | 206 | $185,427 |
| OzempicSemaglutide | 98 | $119,177 |
| DescovyEmtricitabine/Tenofov Alafenam | 54 | $118,079 |
| TrulicityDulaglutide | 99 | $113,637 |
| FarxigaDapagliflozin Propanediol | 108 | $93,819 |
| TivicayDolutegravir Sodium | 28 | $88,405 |
| IsentressRaltegravir Potassium | 45 | $83,514 |
| Egrifta SvTesamorelin Acetate | 11 | $81,813 |
| DovatoDolutegravir Sodium/Lamivudine | 20 | $81,274 |
| JardianceEmpagliflozin | 76 | $70,849 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $62,946 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 16 | $57,039 |
| JanumetSitagliptin Phos/Metformin Hcl | 61 | $49,503 |
| JulucaDolutegravir/Rilpivirine | 14 | $45,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $124,142 | $1,173,546316 claims |
| MerckJanuvia, Isentress, Janumet, Janumet Xr | $1,676 | $327,475323 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Juluca, Triumeq | $48,264 | $258,97374 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,202 | $146,850130 claims |
| Novo NordiskOzempic | $607 | $119,17798 claims |
| Boehringer IngelheimJardiance, Tradjenta | $598 | $98,125113 claims |
| AstraZenecaFarxiga | $1,368 | $93,819108 claims |
| Theratechnologies Inc.Egrifta Sv | $219 | $81,81311 claims |
| GSKTrelegy Ellipta, Arexvy | $161 | $68,524102 claims |
| PfizerEliquis, Nurtec Odt | $35 | $45,41964 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $181 | $32,13122 claims |
| AbbVieLinzess | $406 | $28,32450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.